Algorae Pharmaceuticals Limited (ASX:1AI): What Comes After Its NSW Health Supply Appointment?

Aditi Sarkar

13 November 2026 03:25 PM AEDT

Algorae Pharmaceuticals Limited (ASX:1AI): What Comes After Its NSW Health Supply Appointment?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Algorae Pharmaceuticals (ASX:1AI) traded at AUD 0.009 on 13 November 2026, unchanged.
AlgoraeRx was appointed under an NSW Health public hospital Supply contract.
Five medicine registrations were under Therapeutic Goods Administration review.
A second independent AlgoraeOS validation reported improved combination identification.

Algorae Pharmaceuticals Limited operates a medicine-supply Business and an artificial intelligence-assisted drug discovery programme. Its commercial division, AlgoraeRx, focuses on sourcing, registering and supplying generic and specialty medicines in Australia, while AlgoraeOS supports experimental drug-combination research. Algorae (ASX:1AI) was trading at AUD 0.009 on 13 November 2026, unchanged for the session. Its October announcements describe a public hospital supplier appointment, regulatory preparations and further independent evaluation of its AI platform.

AlgoraeRx and the Medicines Supply Model

Algorae Pharmaceuticals (ASX:1AI) uses a source-register-supply approach through licensing and supply agreements with external manufacturers. This requires selecting products, preparing regulatory submissions and arranging distribution before purchase orders can produce sales. The company identifies Australian institutional medicine supply as a key commercial market, with its broader business description also referring to New Zealand. AlgoraeRx differs from the research-focused AlgoraeOS platform: one seeks to commercialise medicines supplied by Manufacturing partners, while the other investigates possible new drug combinations for future development.

NSW Health Contract and Product Registrations

In its September-quarter activities report issued on 30 October 2026, Algorae stated that AlgoraeRx had been appointed as one of several suppliers under an NSW Health public hospital supply contract. The initial term was three years, with two optional one-year extensions. First supply against purchase orders was expected during the December 2026 quarter. The award is therefore an approved supply route, not a guaranteed quantity of sales. The company also reported five product registrations undergoing review by the Therapeutic Goods Administration. Regulatory decisions and subsequent orders will govern when these products contribute commercial receipts.

Manufacturing Relationships and Commercial Pipeline

The September-quarter report described a licensing and supply network extending to five manufacturing partners and a portfolio of more than 20 products. In October, the company announced an additional licence and supply arrangement with Umedica. Supply agreements provide a framework for bringing medicines to market but do not eliminate registration, quality-control, logistics or tender requirements. Future disclosures can distinguish the number of proposed products from those approved, ordered, delivered and paid for. This distinction is important for interpreting the company's transition from commercial preparation to operating revenue.

AlgoraeOS Validation and Research Context

AlgoraeOS is the company's AI-assisted platform for identifying combinations of therapeutic compounds. Development has involved the UNSW AI Institute and CSIRO Data61, while independent preclinical validation has been undertaken with the Victorian Centre for Functional Genomics at Peter MacCallum Cancer Centre. The company reported that its second validation of AlgoraeOS version two identified approximately 2.5 times the proportion of confirmed synergistic combinations relative to its model predictions than the earlier version. This describes a preclinical comparison, not evidence of improved patient outcomes or regulatory approval for a medicine.

Risks and Near-Term Milestones

Algorae (ASX:1AI) has two distinct execution paths. For AlgoraeRx, revenue timing depends on product registration, successful procurement, manufacturing capacity, delivery and customer orders. For AlgoraeOS, experimental findings require further scientific validation before any licensing or clinical development pathway can be established. The business must fund commercial Working Capital and research expenditure while managing regulatory requirements. A small quoted share price does not, by itself, establish operational progress or the value of either division.

Key Insights

Algorae's latest quarter points to measurable commercial milestones: the beginning of NSW Health orders, additional product decisions and conversion of supply contracts into revenue. The AI platform has reported further preclinical validation, although clinical relevance remains unproven. Subsequent announcements on registrations, delivered products, cash receipts and independent research will clarify the development of both divisions.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.